Iacob Mathiesen

Dr. Mathiesen has a PhD from University of Oslo, Norway. He was a co-founder of Inovio AS, Norway and inventor on numerous electroporation related patents covering devices and methods for gene based immune therapy.

After Inovio AS was acquired by Genetronics Biomedical in 2005 (now Inovio Pharmaceuticals), IM was director of gene delivery at Inovio in San Diego. Iacob has more than 10 years’ experience with IP, electroporation devices and methods and worked closely with University of Southampton to initiate the first human clinical trial using electroporation do delivery a gene based vaccine. Iacob is currently CEO of Otivio AS in Norway, a new startup developing methods and devices for wound healing and temperature management.